Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

9,827.00ZAc
23 Jul 2019
Change (% chg)

-6.00 (-0.06%)
Prev Close
9,833.00
Open
9,810.00
Day's High
9,980.00
Day's Low
9,711.00
Volume
1,036,387
Avg. Vol
1,719,300
52-wk High
29,800.00
52-wk Low
6,899.00

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare Says Foord Asset Management Increased Stake To 5.15 Pct Of Co
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE - FOORD ASSET MANAGEMENT FORMALLY NOTIFIED COMPANY THAT IT HAS INCREASED ITS BENEFICIAL INTEREST IN SECURITIES OF COMPANY.ASPEN PHARMACARE - FOORD ASSET MANAGEMENT INCREASED STAKE TO 5.15% OF ORDINARY SHARE CAPITAL OF COMPANY.  Full Article

Aspen Pharmacare In Talks To Sell Global Infant Nutritionals Business
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS LTD - CURRENTLY ENGAGED IN DISCUSSIONS REGARDING A POSSIBLE DIVESTMENT OF ITS GLOBAL INFANT NUTRITIONALS BUSINESS.  Full Article

Aspen Is Said To Weigh Infant-Formula Unit Sale To Lactalis - Bloomberg
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - :ASPEN IS SAID TO WEIGH INFANT-FORMULA UNIT SALE TO LACTALIS ; BUSINESS COULD FETCH ABOUT $1 BILLION - BLOOMBERG, CITING SOURCES.  Full Article

Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct
Thursday, 8 Mar 2018 

March 8 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍NORMALISED HEADLINE EARNINGS PER SHARE INCREASED BY 26% TO 872 CENTS FOR SIX MONTHS ENDED 31 DECEMBER 2017​.‍HY REVENUE GENERATED BY GROUP GREW 11% TO R21,9 BILLION​.‍PERFORMANCE IN SECOND HALF WILL BENEFIT FROM ADDITIONAL RIGHTS TO AZ ANAESTHETICS FOR FULL SIX MONTHS​.‍ANTICIPATED H2 OPERATING CASH FLOWS WILL REMAIN STRONG; CONVERSION RATE OF 100% OF OPERATING PROFITS IS TARGETED FOR FULL FY.  Full Article

Aspen Expects HY HEPS Between 820.4 To 846.0 Cents Per Share​
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::EXPECTS HY HEADLINE EARNINGS PER TO IMPROVE 28% TO 32% BETWEEN 820.4 TO 846.0 CENTS PER SHARE​.  Full Article

Aspen Pharmacare Receives Approval For Registration Of Alula In China​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​.  Full Article

Aspen Pharmacare Says Has Had No Contact With Viceroy Research
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Aspen Pharmacare Holdings Ltd ::HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT.IS NOT AWARE OF ANY INFORMATION OF A PRICE SENSITIVE NATURE THAT REQUIRES COMMUNICATION TO SHAREHOLDERS​.  Full Article

Mylan And Aspen Announce Launch Of Generic Busulfex Injection
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Mylan Nv ::MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION.MYLAN NV - ‍ANNOUNCED U.S. LAUNCH OF MYLERAN INJECTION, 60 MG/10 ML SINGLE-DOSE VIAL, A GENERIC VERSION OF OTSUKA PHARMACEUTICAL'S BUSULFEX INJECTION​.  Full Article

Aspen Pharmacare says ‍UK CMA opens investigation against company
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aspen Pharmacare Holdings Ltd :‍UK COMPETITION AND MARKETS AUTHORITY HAS OPENED AN INVESTIGATION AGAINST ASPEN​.‍INVESTIGATION INTO ANTI-COMPETITIVE CONDUCT ON SUPPLY OF FLUDROCORTISONE ACETATE 0.1 MG TABLETS, DEXAMETHASONE 2 MG TABLETS IN UK​.‍INVESTIGATION IS AT AN EARLY, INFORMATION-GATHERING STAGE.CMA CONFIRMED THAT, AT THIS TIME, IT HAS NOT REACHED ANY CONCLUSION ON WHETHER COMPETITION LAW HAS BEEN INFRINGED​.‍ASPEN IS NOT CURRENTLY IN A POSITION TO COMMENT ON INVESTIGATION​.  Full Article

Aspen Pharmacare Holdings ‍welcomes SA Competition Commission’s decision not to refer complaint about Aspen
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - ASPEN PHARMACARE HOLDINGS LTD ::‍WELCOMES SOUTH AFRICAN COMPETITION COMMISSION'S DECISION TO DROP ITS INVESTIGATION OF ASPEN FOR SUSPECTED ABUSE OF DOMINANCE AND EXCESSIVE PRICING.  Full Article

South African drugmaker Aspen terminates talks with potential European partner

JOHANNESBURG, July 5 South African drugmaker Aspen Pharmacare said on Friday it had terminated talks with a potential partner in Europe, after announcing in March a strategic review of its European and domestic commercial pharmaceuticals businesses.